Jantien Wanders
147 works · 23,571 citations · h-index 44
Top works
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- New guidelines to evaluate the response to treatment in solid tumors
- Coping with toxicities of docetaxel (TaxotereTM)
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin
- Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group
- Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck
- A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer
- Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- Taxotere toxicity — Protective effects of premedication
- Activity of docetaxel (Taxotere) in small cell lung cancer
- Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
- Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group
- A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck
- Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.